Filing Details

Accession Number:
0000899243-21-005157
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-08 16:05:16
Reporting Period:
2021-02-04
Accepted Time:
2021-02-08 16:05:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1596946 Quotient Ltd QTNT In Vitro & In Vivo Diagnostic Substances (2835) 264719797
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1604628 Jeremy Stackawitz C/O Quotient Limited
28 Esplanade
St Helier Y9 JE2 3QA
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Disposition 2021-02-04 30,000 $5.14 112,926 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Ordinary Shares Employee Stock Option (right to buy) $11.92 2026-05-31 20,000 20,000 Direct
Ordinary Shares Employee Stock Option (right to buy) $15.17 2025-05-19 22,500 22,500 Direct
Ordinary Shares Employee Stock Option (right to buy) $8.00 2024-04-29 60,000 60,000 Direct
Ordinary Shares Employee Stock Option (right to buy) $7.58 2027-05-23 40,000 40,000 Direct
Ordinary Shares Restricted Stock Units $0.00 10,321 10,321 Direct
Ordinary Shares Restricted Stock Units $0.00 23,333 23,333 Direct
Ordinary Shares Restricted Stock Units $0.00 45,000 45,000 Direct
Ordinary Shares Ordinary Share Option (Right to Buy) $4.72 2030-10-31 30,000 30,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2026-05-31 20,000 20,000 Direct
2025-05-19 22,500 22,500 Direct
2024-04-29 60,000 60,000 Direct
2027-05-23 40,000 40,000 Direct
10,321 10,321 Direct
23,333 23,333 Direct
45,000 45,000 Direct
2030-10-31 30,000 30,000 Direct
Footnotes
  1. All 20,000 options have vested and remain exercisable.
  2. All 22,500 options have vested and remain exercisable.
  3. All 60,000 options have vested and remain exercisable.
  4. All 40,000 options have vested and remain exercisable.
  5. Restricted Stock Units convert into ordinary shares on a one-for-one basis.
  6. On May 24, 2018, the Reporting Person was granted 30,961 Restricted Stock Units, of which 20,640 have vested and have been exercised. The remaining 10,321 Restricted Stock Units will vest on May 24, 2021.
  7. On May 24, 2019, the Reporting Person was granted 35,000 Restricted Stock Units, of which 11,667 have vested and have been exercised. The remaining 23,333 will vest in two equal installments on May 24, 2021 and May 24, 2022.
  8. On May 24, 2020, the Reporting Person was granted 45,000 Restricted Stock Units, vesting in three equal annual installments beginning May 24, 2021.
  9. The option vests and becomes exercisable in three equal annual installments beginning October 31, 2021.
  10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.090 to $5.275, inclusive. The Reporting Person undertakes to provide to Quotient Limited and any security holder of Quotient Limited, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (10) to this Form 4.